After almost 12 years of follow‐up, around half of individuals were not on any therapy (ATD or thyroid hormone replacement) and this was not significantly different between TRAb category at diagnosis or cessation of therapy; this is likely to be perceived as an important outcome in people living with Graves' disease. The gene discussed is TG; the disease is Graves disease.